| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Aging and the Growth of Long-Term Care |
0 |
0 |
0 |
243 |
5 |
6 |
8 |
1,300 |
| Aging and the Growth of Long-Term Care |
0 |
0 |
0 |
30 |
2 |
4 |
7 |
149 |
| An Economic Evaluation of the War on Cancer |
0 |
0 |
0 |
97 |
3 |
3 |
4 |
364 |
| Are the Young Becoming More Disabled? |
0 |
0 |
0 |
93 |
3 |
6 |
6 |
352 |
| Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk-Transfer |
0 |
1 |
1 |
153 |
3 |
6 |
8 |
550 |
| Does Medicare Benefit the Poor? New Answers to an Old Question |
0 |
0 |
0 |
67 |
1 |
3 |
4 |
382 |
| Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? |
0 |
0 |
0 |
23 |
0 |
1 |
5 |
41 |
| Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? |
0 |
0 |
0 |
85 |
3 |
5 |
6 |
41 |
| Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey |
0 |
0 |
0 |
55 |
2 |
2 |
2 |
259 |
| Effects of Expanding Health Screening on Treatment - What Should We Expect? What Can We Learn? |
0 |
0 |
0 |
6 |
1 |
2 |
8 |
49 |
| Effects of expanding health screening on treatment – What should we expect? What can we learn? |
0 |
0 |
0 |
6 |
1 |
2 |
3 |
57 |
| Evaluation of Medical Technologies with Uncertain Benefits |
0 |
0 |
0 |
48 |
1 |
2 |
5 |
48 |
| Food Prices and the Dynamics of Body Weight |
0 |
0 |
0 |
71 |
0 |
1 |
1 |
233 |
| HIV Breakthroughs and Risk Sexual Behavior |
0 |
0 |
0 |
84 |
1 |
1 |
2 |
636 |
| Healing the Poor: The Influence of Patient Socioeconomic Status on Physician Supply Responses |
0 |
0 |
0 |
13 |
1 |
2 |
3 |
56 |
| Health Insurance as a Two-Part Pricing Contract |
0 |
0 |
0 |
97 |
3 |
3 |
7 |
432 |
| Health and Access Effects of New Drugs: Combining Experimental and Non-Experimental Data |
0 |
0 |
0 |
52 |
1 |
2 |
3 |
194 |
| Insurance and Innovation in Health Care Markets |
1 |
1 |
1 |
139 |
4 |
7 |
10 |
477 |
| Insurance, Self-Protection, and the Economics of Terrorism |
0 |
0 |
0 |
289 |
0 |
3 |
7 |
893 |
| Insurer Bargaining and Negotiated Drug Prices in Medicare Part D |
0 |
0 |
0 |
32 |
2 |
3 |
4 |
152 |
| Insurers' Negotiating Leverage and the External Effects of Medicare Part D |
0 |
0 |
0 |
14 |
0 |
1 |
4 |
100 |
| Insurers’ Negotiating Leverage and the External Effects of Medicare Part D |
0 |
0 |
0 |
3 |
2 |
3 |
5 |
75 |
| Intellectual Property and Marketing |
0 |
0 |
0 |
91 |
3 |
3 |
6 |
396 |
| Intellectual Property and Marketing |
0 |
0 |
0 |
0 |
4 |
5 |
9 |
12 |
| International Differences in Longevity and Health and Their Economic Consequences |
0 |
0 |
0 |
35 |
0 |
3 |
4 |
126 |
| International Differences in Longevity and Health and their Economic Consequences |
0 |
0 |
0 |
51 |
0 |
1 |
2 |
265 |
| International Differences in Longevity and Health and their Economic Consequences |
0 |
0 |
0 |
55 |
2 |
6 |
9 |
177 |
| Mortality Risk, Insurance, and the Value of Life |
0 |
0 |
0 |
37 |
9 |
11 |
13 |
60 |
| Nonprofit Production |
0 |
0 |
0 |
0 |
1 |
2 |
3 |
198 |
| Nonprofit Production and Competition |
0 |
0 |
2 |
301 |
2 |
4 |
9 |
1,262 |
| Optimal Liability for Terrorism |
0 |
0 |
0 |
40 |
1 |
2 |
4 |
217 |
| Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D |
0 |
0 |
0 |
24 |
0 |
2 |
2 |
98 |
| Risk Preferences Over Health: Empirical Estimates and Implications for Healthcare Decision-Making |
0 |
0 |
0 |
15 |
3 |
4 |
4 |
13 |
| The Declining Quality of Teachers |
0 |
0 |
0 |
222 |
0 |
3 |
6 |
1,703 |
| The Effect of US COVID-19 Excess Mortality on Social Security Outlays |
0 |
0 |
6 |
6 |
2 |
3 |
9 |
9 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
1 |
89 |
1 |
7 |
11 |
379 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
0 |
3 |
5 |
8 |
11 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
492 |
4 |
10 |
11 |
1,614 |
| The Insurance Value of Medical Innovation |
0 |
0 |
1 |
34 |
0 |
0 |
2 |
107 |
| The Rise in Old Age Longevity and the Market for Long-Term Care |
0 |
0 |
1 |
3 |
3 |
4 |
6 |
775 |
| The Rise in Old Age Longevity and the Market for Long-Term Care |
0 |
0 |
0 |
234 |
0 |
0 |
2 |
1,777 |
| The Value of Medican and Pharmaceutical Interventions for Reducing Obesity |
0 |
0 |
0 |
29 |
2 |
4 |
5 |
169 |
| The Welfare Effects of Medical Malpractice Liability |
0 |
0 |
0 |
101 |
0 |
2 |
10 |
477 |
| The Welfare Effects of Public Drug Insurance |
0 |
0 |
0 |
77 |
3 |
3 |
5 |
291 |
| Time-Inconsistency and Welfare |
0 |
0 |
0 |
79 |
5 |
8 |
12 |
389 |
| Understanding Health Disparities Across Education Groups |
0 |
0 |
2 |
398 |
5 |
6 |
15 |
1,710 |
| Understanding the Economic Consequences of Shifting Trends in Population Health |
0 |
0 |
0 |
50 |
2 |
4 |
7 |
184 |
| Understanding the Economic Consequences of Shifting Trends in Population Health |
0 |
0 |
0 |
36 |
0 |
0 |
0 |
111 |
| Understanding the Economic Consequences of Shifting Trends in Population Health |
0 |
0 |
0 |
43 |
0 |
3 |
6 |
229 |
| Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market |
0 |
0 |
0 |
15 |
2 |
5 |
7 |
114 |
| Vaccine Allocation Priorities Using Disease Surveillance and Economic Data |
0 |
0 |
1 |
3 |
7 |
9 |
11 |
25 |
| Total Working Papers |
1 |
2 |
16 |
4,260 |
103 |
187 |
310 |
19,738 |
LogEc is hosted by the
Örebro University School of Business.